167 related articles for article (PubMed ID: 19535524)
1. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
[TBL] [Abstract][Full Text] [Related]
2. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
6. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
[TBL] [Abstract][Full Text] [Related]
8. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
[TBL] [Abstract][Full Text] [Related]
9. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
Tropé A; Jonassen CM; Sjøborg KD; Nygård M; Dahl FA; Alfsen GC; Lie AK
Gynecol Oncol; 2011 Nov; 123(2):257-62. PubMed ID: 21839500
[TBL] [Abstract][Full Text] [Related]
10. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
Broccolo F; Fusetti L; Rosini S; Caraceni D; Zappacosta R; Ciccocioppo L; Matteoli B; Halfon P; Malnati MS; Ceccherini-Nelli L
J Med Virol; 2013 Mar; 85(3):472-82. PubMed ID: 23280876
[TBL] [Abstract][Full Text] [Related]
11. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.
Molden T; Kraus I; Skomedal H; Nordstrøm T; Karlsen F
J Virol Methods; 2007 Jun; 142(1-2):204-12. PubMed ID: 17379322
[TBL] [Abstract][Full Text] [Related]
12. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.
Andersson S; Hansson B; Norman I; Gaberi V; Mints M; Hjerpe A; Karlsen F; Johansson B
Int J Oncol; 2006 Sep; 29(3):705-11. PubMed ID: 16865288
[TBL] [Abstract][Full Text] [Related]
13. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
[TBL] [Abstract][Full Text] [Related]
14. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
15. Type-dependent E6/E7 mRNA expression of single and multiple high-risk human papillomavirus infections in cervical neoplasia.
Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
J Clin Virol; 2012 May; 54(1):61-5. PubMed ID: 22326759
[TBL] [Abstract][Full Text] [Related]
16. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
Kraus I; Molden T; Holm R; Lie AK; Karlsen F; Kristensen GB; Skomedal H
J Clin Microbiol; 2006 Apr; 44(4):1310-7. PubMed ID: 16597856
[TBL] [Abstract][Full Text] [Related]
17. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening.
Andersson S; Mints M; Weiderpass E; Johansson B
Curr Pharm Des; 2013; 19(8):1508-15. PubMed ID: 23072430
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
Ovestad IT; Vennestrøm U; Andersen L; Gudlaugsson E; Munk AC; Malpica A; Feng W; Voorhorst F; Janssen EA; Baak JP
Gynecol Oncol; 2011 Nov; 123(2):278-83. PubMed ID: 21835440
[TBL] [Abstract][Full Text] [Related]
20. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
